Privi Speciality Chemicals Ltd held its Q2 FY27 earnings call on October 29, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.
Record Quarter on Sales, Profitability and Cash Flow
Highest-ever quarterly revenue of Rs.773.16 crore — up 13.9% YoY vs Q2 FY 2025-2026, with EBITDA at Rs.212.49 crore (+16.66% YoY) and PAT at Rs.117.03 crore (+24.61% YoY), supported by broad-based demand across domestic and export markets.
EBITDA margin of 27.48% in Q2 FY 2026-2027 vs 26.12% in the comparative periods, maintained despite feedstock and freight cost volatility; aided by operational efficiencies, disciplined expense management and improved product mix.
H1 FY 2026-2027 PAT of Rs.201 crore — up ~29% YoY vs H1 FY 2025-2026; H1 volume growth was ~7-7.5% YoY (Q2 volume growth 4% YoY) — actuals, not guidance.
First-ever interim dividend of Rs.5 per share (face value Rs.10) declared for FY 2026-2026-2027, which management framed as reflecting confidence in the business.
Raw material cost at 52% of sales in Q2 FY 2026-2027 vs 54% in Q1 FY 2026-2027 and 51% in Q2 FY 2025-2026; normalizing for incentive revenue, RMC was ~52% vs ~51% prior year, a 1-2% gap the CFO attributed to CST/GST factors across billing locations.
Higher other income in Q1-Q2 FY 2026-2027 was driven primarily by foreign exchange gains, as the company is a net exporter and dollar movement has been in its favor (CFO Narayan S. Iyer).
Q2 seasonality caveat — management said Q2 has consistently been the strongest quarter over the last 4-5 financial years, aided by second calendar year customer contracts and newer products; this is not strict seasonality per management, but implies H2 comparisons should be made carefully.
20% annual growth guidance reaffirmed for FY 2026-2027 despite H1 FY 2026-2027 growth of ~15%; CFO Narayan S. Iyer noted H1 is typically lower than H2 for the company and urged evaluating performance annually rather than quarter-on-quarter.
Analyst pushback on the math — Ram Aravan flagged that reaching 20% for FY 2026-2027 implies H2 FY 2026-2027 growth above 22-23%; management did not provide segment-level guidance to bridge the gap.
Plant utilization at 85-90% currently, with management expecting to maintain growth momentum across all plants and growth expected across all segments.
Demand context per CMD Mahesh Babani — usage of aroma chemicals is increasing significantly with new applications and users emerging, and the Africa market is growing; Privi supplies customers who in turn serve Africa.
European headwinds framed as opportunity — Mahesh Babani said European labor and energy crises may not affect the company given its exposure to daily-use products, and are creating opportunities for Indian manufacturers that are compliant, quality-conscious and follow sustainability norms.
Debottlenecking expansion completed (originally targeted for commissioning by September 2026, FY 2026-2027); partial volume benefit expected in Q3 FY 2026-2027 and significant volume growth in Q4 FY 2026-2027 as new annual contracts commence, with utilization of almost 85-90% on expanded capacity guided for Q4 FY 2026-2027. No further debottlenecking is planned.
Total three-phase capex of ~Rs.1,400 crore (period unspecified) per CFO Narayan S. Iyer; Phase 1 is complete, part of Phase 2 spend is incurred, and ~Rs.1,000 crore remains for Phases 2 and 3 (period unspecified).
Phase 2 (maltol, ethyl maltol, furfural, cyclopentanone) — completion expected between June and September of FY 2027-2028, with revenue contribution starting from October 2027 (Q3 FY 2027-2028) onwards; expected to contribute ~Rs.1,000 crore of revenue at full capacity of 12,000 MT (full run-rate period unspecified).
Phase 3 entails capex of ~Rs.400-425 crore to add ~Rs.450-500 crore of incremental revenue (period unspecified), while Phase 1 carries revenue potential of ~Rs.450 crore (period unspecified).
Rs.5,000 crore revenue mark by 2030 — management expects the aggregate three-phase revenue potential (first indicated at Rs.1,700-1,800 crore, later itemized to ~Rs.1,900 crore) to be "completely in sync by 2030," enabling the Rs.5,000 crore mark. Management is "very confident" of its "5K, 1K plus" vision by 2030.
Asset turnover at 1.7x on the fixed asset base as of Q2 FY 2026-2027; the CFO expects better asset turnover with new molecules and high specialty chemicals in Phase 2 and Phase 3 (period unspecified).
Two strategic partnerships/JVs flagged in Q1 FY 2026-2027 remain work in progress — agreements not yet signed, with updates promised "in due course" and no committed timeline.
Merger Approvals and Permissions Gate the FY28 Recovery
Prior guidance shortfall acknowledged — analyst Krish Salot (Veer Growth AIF) flagged that Privi Fine Science was earlier guided to ~Rs.100 crore turnover by FY25 but delivered ~Rs.68 crore in FY26 at a loss of ~Rs.34.28 crore, versus the plant's original maximum revenue target of ~Rs.300 crore (period unspecified); management confirmed that guidance had been given.
Merger awaiting regulatory approvals — the Privi Fine Science–Privi Biotechnology merger is expected to complete before end of FY 2026-2027; approval delays are "nearing completion" and products are ready.
Capacity constraints pending permissions — utilization is ~85% on installed capacity of 6,000 MTPA (potential revenue ~Rs.300-350 crore at prevailing prices, period unspecified), but expansion cannot proceed pending permissions including from the Pollution Control Board, which management expects "anytime now" / within the next few months.
FY 2027-2028 improvement guided — management expects revenue to move from the ~Rs.100 crore level to the Rs.250-300 crore mark at 80-85% utilization once pending permissions are in place; break-even will be achieved only once the pending permissions are received.
Prijiw JV turned profitable in Q2 — sales of ~Rs.28 crore with positive PBT of close to Rs.2 crore in Q2 FY 2026-2027; H1 FY 2026-2027 sales of ~Rs.47 crore with a negligible loss of Rs.0.02 lakhs.
JV revenue guided at ~Rs.225 crore for FY27 and FY28 — supported by two expansion phases, one already underway; a third phase is under evaluation (pilot studies plus feasibility, economics and financials work in progress), with guidance possible only after ~3-6 months from the call; if completed, revenue could go beyond Rs.225 crore (period unspecified).
Working Capital at Sub-100 Days; Deleveraging in Process
Working capital cycle below 100 days in Q2 FY 2026-2027 vs 124 days in Q2 FY 2025-2026; analyst Nikhil Porwal noted days near 90 currently vs almost 160 three years ago, and the CFO guided to a long-term annual cycle of about 105-110 days (period unspecified) without explicitly confirming whether current levels mark a bottom.
Cash generated from operations at Rs.445 crore in H1 FY 2026-2026-2027 — a marked improvement over the prior year, mainly on higher profits; management also confirmed an analyst's observation of operating cash flow at ~Rs.360 crore (period unspecified) as evidence of improved EBITDA-to-cash conversion.
Balance sheet as on 30 September 2026 — ROCE 24.30% (+216 bps YoY), ROE 26.34% (+134 bps YoY), net debt Rs.814.51 crore, net debt/EBITDA 1.07x, net debt/equity 0.51.
Receivables declined vs March (FY 2025-2026 year-end) even as sales rose in H1 FY 2026-2027; the CFO attributed this to Privi's quality on delivery time and customers paying on time — in some cases a few days early — rather than any stated change in customer payment terms.
Debt-to-advance conversion still in process — negotiations with large multinational companies take time; no completion timeline was provided (period unspecified).
State incentives lagging — Rs.1.62 crore received in H1 FY 2026-2027 vs Rs.9 crore in FY 2025-2026; the CFO said FY 2026-2027 receipts should exceed the FY 2025-2026 level, with the outstanding Rs.12-15 crore expected over H2 FY 2026-2027.
Freight pass-through mechanism embedded — customer contracts now include a quarterly freight pricing mechanism, enabling pass-through of drastic freight increases or decreases; management noted its freight disruption has not been to the extent peers are facing, and ~70% (two-thirds) of revenue comes from non-petroleum-source raw materials, limiting West Asia conflict impact.
FY28 Growth and Margin Guidance; Offtake Still Being Finalized
FY 2027-2028 revenue guided "close to Rs.4,000 crore, maybe Rs.3,750 crore" — management is confident of maintaining or beating 20% revenue growth in FY 2027-2028, citing initial customer ("first cut") indications of higher offtake.
EBITDA margin expected to be maintained in FY 2027-2028 — CMD Mahesh Babani said the company expects to hold its current EBITDA margin level; new products launching in FY 2027-2028 are expected to deliver margins in the same range as current levels (no specific percentage quantified).
Overall ~20% growth expected in coming years (period unspecified), with capital allocation continuing toward capacity expansion, new specialty products and operational improvements while maintaining focus on profitable growth and cash generation.
FY 2027-2028 contract negotiations characterized as "extremely good" — Mahesh Babani declined specifics citing the proprietary nature of discussions but described a "very positive outlook" for the market and customers.
Offtake tie-ups for new capacity not yet finalized — for capacity expected on stream around September-October 2027 (H2 FY 2027-2028), tie-ups are still being worked on; customer approval cycles are ongoing (confirmed to Dharmendra Dave, JM Financial Limited). During the 1-year build-out, Privi plans pilot-basis production and sales to sort out quality issues before commercial production starts.
Sourcing diversification — on imported raw materials CTO and GTO, the CFO stated sourcing is "very diversified" with no supplier concentration indicated.
Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.
Powered by Cofacto — AI research platform for Indian stocks, every claim cited from primary filings